Skip to main content
  • Home
  • Structural Heart Disease

Structural Heart Disease

HCM in Review: Highlights of 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments
  • Summarise results from ongoing trials with experimental treatments
See more
HCM in Review: Assessing SCD Risk in HCM & Managing HCM With High Risk SCD
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall risk factors associated with sudden cardiac death (SCD)
  • Recall best practice approaches to prevent SCD according to guidelines and expert insight
  • Stratify patients likely to benefit from invasive procedures versus pharmacological treatment
See more
Severe Aortic Stenosis: Stratifying Patients for Lifetime Management
  • 1 EBAC

Learning objectives

  • Describe the challenges with lifetime management in severe AS in both a SAVR and TAVI-first scenario
  • Summarise clinical evidence for TAVI in low surgical risk patients
  • Recall different guideline recommendations for SAVR and TAVI approaches
  • Assimilate current clinical knowledge with patient preferences when formulating treatment plans for severe AS patient
See more
Hypertrophic Cardiomyopathy in Review: ESC–HFA 2022 & How to Differentiate HCM From Its Phenocopies
  • 0.50 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
  • Differentiate the signs and symptoms of HCM from other conditions that frequently mask, or mimic the disease and in the presence of comorbidities
See more
Hypertrophic Cardiomyopathy in Review: Highlights of ACC 2022
  • 0.25 AMA PRA Credit

Learning objectives

  • Recall the efficacy and safety of existing HCM treatments and summarise results from ongoing trials with experimental treatments
See more
Getting it Right First Time in Severe Aortic Stenosis - Key insights for Long Term Success
  • 1 EBAC

Learning objectives

  • Recall current and predicted trends in TAVI with respect to preserving coronary access
  • Consider determining factors for choosing valves in low risk populations
  • Discuss solutions for maximising valve durability and haemodynamics and for treating degenerated TAVI
See more